Mature Medicines Divestment Signals Shift in Manufacturing Strategy

Sanofi and Cheplapharm have announced plans for a strategic partnership that would transfer 20 mature medicines and three manufacturing sites from Sanofi to Cheplapharm.¹ In exchange, Sanofi will receive a 26.4% equity stake in Cheplapharm, extending a commercial relationship between the two organizations that dates to 2014.

The agreement covers manufacturing facilities in Csanyikvölgy, Hungary, Jurong, Singapore, and Ploërmel, France.¹ Existing employment arrangements and collective agreements at each site are expected to remain in place as operations transition. Among the products included in the divestment is Lovenox/Clexane (enoxaparin), a widely used anticoagulant, though the transfer of US rights is excluded from the deal.

Why Are Large Innovator Companies Divesting Mature Product Lines?

The transaction reflects a pattern of companies with substantial R&D pipelines separating legacy, off-patent products from the innovation-focused portfolios that drive future growth.¹ This trend carries direct operational implications as mature medicines typically require different production economics, regulatory maintenance schedules, and commercial support structures than newly launched therapies. Consolidating those assets under specialists better equipped to manage them can extend product lifecycles while freeing capital and technical resources for pipeline investment.

"Our multi-year journey to simplify our mature portfolio has enabled us to focus on innovation while ensuring mature medicines continue to reach patients who need them," said Thomas Grenier, executive vice president, General Medicines, Sanofi, in a press release.¹ He added that the transaction "significantly builds on its prior acquisitions from Sanofi's mature medicines portfolio," and framed the equity stake as reinforcing a broader commitment to supporting established treatments alongside new drug development.

What Does This Mean for the Transferred Manufacturing Sites?

For personnel and stakeholders at the three affected facilities, continuity of operations is a central feature of the proposed arrangement.¹ Sanofi and Cheplapharm have stated they will work closely together during the transition to maintain supply continuity and uphold manufacturing quality standards throughout the changeover. This is particularly relevant, as one of the products involved, enoxaparin, is a complex biologic-adjacent product requiring specialized production expertise, precisely the kind of technical capability the deal is intended to preserve rather than disrupt.

Edeltraud Lafer and Sebastian Braun, Co-CEOs of Cheplapharm, addressed this directly in a joint statement, in the press release,¹ "This represents a long-term pharmaceutical and industrial commitment: to invest in our sites and their expertise, to preserve rare skills, and to ensure the long-term availability of these treatments for patients."

For professionals tracking portfolio realignment across the pharmaceutical sector, this deal illustrates a broader strategic calculus: mature, off-patent medicines and innovative pipeline candidates increasingly demand distinct operating models, regulatory strategies, and manufacturing investments.¹ As more companies pursue similar separations, the specialized mature-medicines segment, and the manufacturing capacity that supports it, is likely to see continued consolidation activity in the months ahead.

How Does the Deal Fit into the Broader M&A Landscape?

The Sanofi-Cheplapharm transaction arrives amid one of the largest waves of patent expirations in the biopharmaceutical industry's history, with more than $200 to $300 billion in yearly sales projected to be at risk as exclusivity lapses on blockbuster drugs treating cancer, heart disease, immune disorders, diabetes, and eye disease.² Industry data indicates the top 20 drugs nearing the patent cliff accounted for 176 billion dollars in revenue in 2025 alone.

Rather than pursuing outright acquisitions, which carry the full risk of bringing a product to market, many companies have shifted toward asset-level transactions, licensing arrangements, and structured alliances, including joint ventures and minority investments paired with future acquisition options.² Average deal sizes roughly doubled in 2025 to approximately $2 billion, even as overall deal volume declined, reflecting a more selective, buyer-cautious market shaped by financing constraints, tariff uncertainty, and drug pricing pressures.

Against this backdrop, the equity-based structure of the Sanofi-Cheplapharm partnership reflects a broader industry pattern: companies are increasingly favoring measured, structured arrangements over conventional buyouts to manage risk while still repositioning their portfolios ahead of a transaction-intensive 2026.²

References

1. Sanofi and Cheplapharm. Sanofi and Cheplapharm to create new strategic partnership in mature medicines. GlobeNewswire. Press Release. September 14, 2026. https://www.globenewswire.com/news-release/2026/09/14/3361178/0/en/press-release-sanofi-and-cheplapharm-to-create-new-strategic-partnership-in-mature-medicines.html
2. Aljamal M. Off the cliff, into the deal room: pharma M&A in 2026 and beyond. Inquisitive Minds. Bristows LLP. Feburary 13, 2026. https://inquisitiveminds.bristows.com/post/102midb/off-the-cliff-into-the-deal-room-pharma-ma-in-2026-and-beyond